Lenalidomid Hcs (Lenalidomide)

Lenalidomide is used in the management of hematologic malignancies and related disorders.

• Multiple myeloma: improves progression‑free survival and overall response when used in combination or as maintenance therapy.
• Myelodysplastic syndromes with del(5q): reduces transfusion dependence and induces cytogenetic remission.
• Multiple myeloma (maintenance): prolongs disease‑free interval after initial induction and autologous stem‑cell transplantation.

• Lenalidomide binds to the cereblon component of the CRL4‑E3 ubiquitin ligase complex, altering substrate specificity and promoting ubiquitination of the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3). Their degradation leads to reduced tumor cell proliferation, inhibition of angiogenesis, and enhanced immune‑mediated tumor cell killing, underpinning its antineoplastic activity. It also modulates cytokine production and co‑stimulatory molecule expression on T cells and natural killer cells, further contributing to its immunomodulatory effects.

Lenalidomide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Fatigue: persistent tiredness or lack of energy.
• Diarrhea: loose or watery stools.
• Nausea: feeling of sickness or urge to vomit.
• Rash: mild skin irritation or redness.
• Constipation: difficulty passing stools.
• Peripheral neuropathy: tingling or numbness in extremities.

Serious or Rare Side Effects

• Thromboembolic events: deep vein thrombosis or pulmonary embolism.
• Severe neutropenia: markedly low neutrophil count increasing infection risk.
• Severe thrombocytopenia: low platelet count leading to bleeding.
• Secondary primary malignancies: emergence of new cancers.
• Hepatotoxicity: liver enzyme elevations or liver injury.
• Hypersensitivity reactions: severe skin reactions or anaphylaxis.

When prescribing Lenalidomide, clinicians should observe several precautions to minimize risks.

• Pregnancy risk: contraindicated in pregnancy (Category X); ensure effective contraception for both male and female patients.
• Thromboembolic prophylaxis: assess risk and consider anticoagulation in patients with additional risk factors.
• Renal impairment: adjust dose or monitor closely in patients with reduced kidney function.
• Hematologic monitoring: perform regular complete blood counts to detect neutropenia or thrombocytopenia.
• Infection vigilance: monitor for signs of infection due to immunosuppression.
• Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and direct sunlight.

Lenalidomide interacts with several medicines; awareness of these interactions helps avoid adverse outcomes.

Major Interactions (Avoid)

• Strong CYP3A4 inducers: agents such as rifampin may markedly reduce lenalidomide exposure.
• Anticoagulants: concurrent use with warfarin can increase bleeding risk.
• Immunosuppressants: high‑dose steroids may diminish immunomodulatory effects.

Moderate Interactions (Monitor Closely)

• P-glycoprotein substrates: drugs like digoxin may have altered plasma levels.
• NSAIDs: may increase risk of gastrointestinal bleeding.
• Vaccines: live attenuated vaccines should be avoided due to impaired immune response.